Acquisition of 51% of generic drug manufacturer Copley Pharmaceutical by Hoechst Celanese completed, Hoechst announces Nov. 11. The tender offer for 9.93 mil. shares of Copley common stock at $55 per share, or about $546 mil., was announced Oct. 9 and the tender offer began Oct. 15 ("The Pink Sheet" Oct. 18, p. 3). Hoechst Celanese says a total of approximately 17.1 mil. shares, "including approximately 8,818,026 shares subject to guarantees of delivery," actually were tendered.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth